NO20051187L - Depotformuleringer bestaende av aktive arylheterocykliske forbindelser i form av en suspensjon - Google Patents

Depotformuleringer bestaende av aktive arylheterocykliske forbindelser i form av en suspensjon

Info

Publication number
NO20051187L
NO20051187L NO20051187A NO20051187A NO20051187L NO 20051187 L NO20051187 L NO 20051187L NO 20051187 A NO20051187 A NO 20051187A NO 20051187 A NO20051187 A NO 20051187A NO 20051187 L NO20051187 L NO 20051187L
Authority
NO
Norway
Prior art keywords
depositional
suspension
active
formulations consisting
arylheterocyclic
Prior art date
Application number
NO20051187A
Other languages
English (en)
Norwegian (no)
Inventor
Jaymin Chandrakant Shah
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20051187L publication Critical patent/NO20051187L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20051187A 2002-10-25 2005-03-04 Depotformuleringer bestaende av aktive arylheterocykliske forbindelser i form av en suspensjon NO20051187L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42129502P 2002-10-25 2002-10-25
PCT/IB2003/004535 WO2004037224A1 (en) 2002-10-25 2003-10-13 Depot formulations of arylheterocyclic active agents in the form of a suspension

Publications (1)

Publication Number Publication Date
NO20051187L true NO20051187L (no) 2005-04-11

Family

ID=32176696

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051187A NO20051187L (no) 2002-10-25 2005-03-04 Depotformuleringer bestaende av aktive arylheterocykliske forbindelser i form av en suspensjon

Country Status (21)

Country Link
US (1) US20040146562A1 (pl)
EP (1) EP1562546A1 (pl)
JP (2) JP2006505579A (pl)
KR (1) KR20050071611A (pl)
CN (1) CN1703198A (pl)
AR (1) AR041826A1 (pl)
AU (1) AU2003267763A1 (pl)
BR (1) BR0315663A (pl)
CA (1) CA2498276A1 (pl)
GT (1) GT200300227A (pl)
MX (1) MXPA05004299A (pl)
NL (1) NL1024616C (pl)
NO (1) NO20051187L (pl)
PA (1) PA8586301A1 (pl)
PE (1) PE20040471A1 (pl)
PL (1) PL375603A1 (pl)
RU (1) RU2292207C2 (pl)
TW (1) TW200418477A (pl)
UY (1) UY28035A1 (pl)
WO (1) WO2004037224A1 (pl)
ZA (1) ZA200501979B (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
DE60327225D1 (de) 2002-08-20 2009-05-28 Bristol Myers Squibb Co Aripiprazol-komplex-formulierung und verfahren
ATE482695T1 (de) 2002-12-13 2010-10-15 Durect Corp Orale darreichungsform mit flüssigen hochviskosen trägersystemen
CA2525868A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Anxiety treatments with ziprasidone
WO2006000913A1 (en) * 2004-06-23 2006-01-05 Pfizer Products Inc. Method for sterile filtration of viscous pharmaceutical compositions
BRPI0515372B8 (pt) * 2004-09-17 2021-05-25 Durect Corp composição líquida para fornecer anestesia local prolongada após administração a um indivíduo, e, uso de bupivacaína, acetato isobutirato de sacarose e álcool benzílico
US20080254114A1 (en) * 2005-03-03 2008-10-16 Elan Corporation Plc Controlled Release Compositions Comprising Heterocyclic Amide Derivative Nanoparticles
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
CN100391458C (zh) * 2006-02-07 2008-06-04 上海医药工业研究院 齐拉西酮或其盐包合物制备方法
MX2008014283A (es) * 2006-05-09 2008-11-18 Astrazeneca Ab Formulacion parental la cual comprende un inhibidor de bomba de protones esterilizado en su recipiente final por radiacion de ionizacion.
PL2117521T3 (pl) 2006-11-03 2012-11-30 Durect Corp Transdermalne systemy dostarczania zawierające bupiwakainę
WO2009075782A1 (en) * 2007-12-06 2009-06-18 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
CA2905131A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
US12274794B2 (en) 2016-07-06 2025-04-15 Orient Pharma Co., Ltd. Oral dosage form with drug composition, barrier layer and drug layer
WO2018153315A1 (zh) 2017-02-23 2018-08-30 上海华汇拓医药科技有限公司 一种多奈哌齐半帕莫酸盐的粉针剂、包含其的组合物及它们的制备方法
CA3167217A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
CN116940358A (zh) 2021-01-12 2023-10-24 度勒科特公司 持续释放药物递送系统和有关的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989002265A1 (fr) * 1987-09-07 1989-03-23 Teijin Limited Emulsion grasse contenant un medicament, du type prepare immediatement avant l'utilisation, et procede de preparation d'une telle emulsion grasse contenant un medicament
GB9200247D0 (en) * 1992-01-07 1992-02-26 Erba Carlo Spa Pharmaceutical compositions containing polymer derivative-bound anthracycline glycosides and a method for their preparation
JP3954115B2 (ja) * 1992-07-28 2007-08-08 アストラゼネカ・アクチエボラーグ 注射剤および注射剤キット
US5594141A (en) * 1994-11-23 1997-01-14 Neurogen Corporation Certain aminomethyl biphenyl, aminomethyl phenyl pyridine and aminomethyl phenyl pyrimidine derivatives; novel dopamine receptor subtype selective ligands
US6040295A (en) * 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
DK0811386T3 (da) * 1996-05-07 2005-01-03 Pfizer Fremgangsmåde til udvælgelse af et salt til fremstilling af et inklusionskompleks
JP2002512597A (ja) * 1996-12-20 2002-04-23 アルザ コーポレイション 注射可能な貯留槽ゲル組成物およびこの組成物の製造方法
KR20010012374A (ko) * 1997-05-16 2001-02-15 스티븐 엠. 오드레 지속 효과를 갖는 서방성 겔
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
PL196867B1 (pl) * 1999-05-27 2008-02-29 Pfizer Prod Inc Kompozycja zyprazydonu
MY137726A (en) * 2000-11-22 2009-03-31 Nycomed Gmbh Freeze-dried pantoprazole preparation and pantoprazole injection
JP4334229B2 (ja) * 2001-03-20 2009-09-30 サイデックス・ファーマシューティカルズ・インコーポレイテッド プロポフォール及びスルホアルキルエーテルシクロデキストリン含有製剤
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
IL160306A0 (en) * 2001-08-31 2004-07-25 Univ Rockefeller Method for classification of anti-psychotic drugs

Also Published As

Publication number Publication date
PE20040471A1 (es) 2004-08-14
RU2292207C2 (ru) 2007-01-27
AU2003267763A1 (en) 2004-05-13
UY28035A1 (es) 2004-05-31
CN1703198A (zh) 2005-11-30
KR20050071611A (ko) 2005-07-07
NL1024616C (nl) 2010-04-19
AR041826A1 (es) 2005-06-01
BR0315663A (pt) 2005-08-30
MXPA05004299A (es) 2005-08-03
US20040146562A1 (en) 2004-07-29
PL375603A1 (pl) 2005-12-12
NL1024616A1 (nl) 2004-04-27
CA2498276A1 (en) 2004-05-06
ZA200501979B (en) 2006-04-26
JP2006219501A (ja) 2006-08-24
WO2004037224A1 (en) 2004-05-06
EP1562546A1 (en) 2005-08-17
TW200418477A (en) 2004-10-01
RU2005112202A (ru) 2005-11-20
JP2006505579A (ja) 2006-02-16
PA8586301A1 (es) 2004-05-07
GT200300227A (es) 2004-06-23

Similar Documents

Publication Publication Date Title
DK1299348T3 (da) Forbindelser og sammensætninger til levering af aktive midler
NZ542138A (en) Heterobifunctional polymeric bioconjugates
WO2004098494A3 (en) Compounds, compositions, and methods
EA200701065A1 (ru) Инъецируемые составы, содержащие нанодисперсный оланзапин
MXPA06012595A (es) Analogos de amino-tetrazoles y metodos de uso.
DK1819353T3 (da) Sammensætning til proteasomhæmning
NO20066055L (no) Pyridinderivater
MXPA03006093A (es) Derivados de n(fenilsulfonil)glicina y su uso terapeutico.
NO20072515L (no) 2-amido-4-fenyltnazolderivater, fremstilling og terapeutsik anvendelse derav
EA200501928A1 (ru) Пирролодигидроизохинолины как ингибиторы pde10
DK1268471T3 (da) N-heterocykliske derivater som NOS-inhibitorer
ATE484508T1 (de) Furylverbindungen
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
CY1110034T1 (el) Παραγωγα 1,2,4,5-τετραϋδρο-3h-βενζαζεπινων, μεθοδος παρασκευης αυτων και οι φαρμακευτικες συνθεσεις που τα περιεχουν
UY28035A1 (es) Formulaciones de liberacion prolongada en forma de suspension
CY1107028T1 (el) Παραγωγα ινδανυλ-πιπεραζινων μεθοδος παρασκευης αυτων και οι φαρμακευτικες συνθεσεις που τα περιεχουν
WO2005028474A3 (en) Pyrazoloquinoline derivatives as chk-1 inhibitors
NO20054787L (no) Indenderivater som farmasotiske midler
NO20050666L (no) 2,7-substituerte indoler og deres anvendelse som 5-HT6 modulatorer
WO2004112771A8 (en) Pharmaceutical compositions including an antihistamine and a stimulant and use thereof
IL173810A0 (en) Imidazopyridine derivatives and pharmaceutical compositions containing the same
CY1106376T1 (el) Δικυκλικα παραγωγα των αμινο-πυραζινονων, μεθοδος παρασκευης τους και οι φαρμακευτικες συνθεσεις που τα πepιεχουν
UY28148A1 (es) Bromhidrato de escitalopram y un metodo para su preparacion
WO2004062562A3 (en) Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
WO2005061496A8 (en) Aminopyridine-derivatives as inductible no-synthase inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application